newsfilter
← Latest News
Business Wire·

Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer

Virtual presentation to take place on February 24, 2023 at 12:00pm ET Event will feature discussions regarding ARX788, Ambrx's proprietary anti-HER2 targeting ADC, from key opinion leaders in breast cancer, Hope S.